Botox vs Xeomin Onset and Duration at UH CELL Clinic Gangnam
UH CELL Clinic Gangnam, near Gangnam Station in Seoul, lists Botox on its treatment menu; this page sets out how Botox (onabotulinumtoxinA) differs from Xeomin (incobotulinumtoxinA) in formulation, onset and duration for glabellar lines.
Botox and Xeomin are both licensed botulinum toxin type A injections used to soften glabellar lines, and UH CELL Clinic Gangnam, a lifting and anti-aging clinic near Gangnam Station in Seoul, lists Botox on its published treatment menu. The two toxins are not identical formulations. Botox is the brand name for onabotulinumtoxinA, made by Allergan, part of AbbVie in the United States, and it keeps the accessory complexing proteins that form around the neurotoxin during fermentation. Xeomin is the brand name for incobotulinumtoxinA, made by Merz Pharmaceuticals in Germany, and its manufacturing process removes those complexing proteins, leaving the purified 150 kDa neurotoxin alone. The sections below set out that formulation difference in full, how onset and duration compare, and how a patient at UH CELL Clinic Gangnam checks which product is actually in the vial.
Botox Treatment at UH CELL Clinic Gangnam
UH CELL Clinic Gangnam lists Botox on its published English-language treatment menu, alongside dermal filler, Sculptra and Juvelook. The clinic's own Korean-language page on skin Botox describes a shallow, low-dose technique spread broadly across the facial skin layer for pores and fine lines, a different use from the deeper, muscle-targeted dosing this Botox-versus-Xeomin comparison concerns. Muscle-targeted dosing for the forehead and glabella is the use UH CELL also lists at its network of branches, including the Seocho branch's botulinum toxin page.
UH CELL's team includes interpreter staff who can assist in Japanese, Chinese and English, and the clinic's materials describe patients visiting from Japan, Taiwan, China and English-speaking countries. For a visitor weighing Botox against Xeomin before a trip to Seoul, that language support applies at the consultation stage, where the specific product and dose get discussed before any injection.
UH CELL's own news platform publishes a checklist for confirming genuine injectable product at any clinic: a sealed box, an authentication sticker, a certification number, and watching the product opened before use, set out in an article on pricing and product authenticity. UH CELL's menu names Botox as a general treatment rather than naming a manufacturer, so that checklist is the practical way a patient confirms, at consultation, whether the vial being opened is labeled onabotulinumtoxinA, incobotulinumtoxinA or another approved toxin.
Two branded products anchor the rest of this comparison. Botox is the brand Allergan, part of AbbVie in the United States, uses for onabotulinumtoxinA, a botulinum toxin type A injection sold to licensed medical practices. Xeomin is the brand Merz Pharmaceuticals, headquartered in Germany, uses for incobotulinumtoxinA, a purified botulinum toxin type A injection also sold to licensed medical practices. The table below sets out how their formulation, onset and duration compare.
Complexing Proteins and Formulation Differences
UH CELL Clinic Gangnam names its injectable neuromodulator treatment Botox on its menu without listing which manufacturer's vial a given appointment uses, and that detail is exactly what separates onabotulinumtoxinA from incobotulinumtoxinA. Botox's manufacturing process keeps the complexing proteins that form around the 150 kDa botulinum neurotoxin during fermentation, so each vial contains the neurotoxin bound to those accessory proteins, formulated with human serum albumin and sodium chloride. Xeomin's manufacturing process strips the complexing proteins away during purification, so each vial contains the 150 kDa neurotoxin alone, formulated with human serum albumin and sucrose.
The "a" in each nonproprietary name marks a type A botulinum toxin; the prefix marks the process behind it, onabotulinumtoxinA for Botox and incobotulinumtoxinA for Xeomin. Units of one aren't interchangeable with units of the other. Regulatory labeling treats each brand's dosing unit as specific to that product. A dose written in Botox units follows its own unit system, numerically different from Xeomin units, and a clinician switching a patient between the two brands sets a new dose for the product in hand.
Merz has also marketed the absence of complexing proteins in Xeomin as a reason repeat dosing might carry a lower chance of triggering neutralizing antibodies over time. That claim comes from Xeomin's manufacturer.
Onset and Duration for Glabellar Lines
UH CELL Clinic Gangnam lists glabellar-line treatment among its forehead and brow injectable services, the same indication Botox's and Xeomin's own cosmetic trials most often report onset and duration against. Each maker ran separate clinical trials. The onset and duration ranges in the table above come from those separate trial programs, not from one head-to-head comparison between the two products.
No FDA label statement declares either product faster to take effect or longer lasting than the other for glabellar lines. A claim of faster onset or longer duration in either brand's marketing material reflects that maker's trial data, not a regulatory finding against the competing brand.
If you are comparing the two before a consultation, ask the injector which product is going into the syringe and request to see the box before it opens, a step that works the same way for either brand. Onset and duration also depend on dose, injection site and individual muscle activity, so the ranges in the table describe trial averages, not a guarantee for any one person.
Checking Which Product You Receive at UH CELL Clinic Gangnam
UH CELL Clinic Gangnam operates near Gangnam Station at 13 Teheran-ro 8-gil, Seoul, in the WD Building, with hours of 10:00 to 20:00 on Monday, Tuesday, Wednesday and Friday and 10:00 to 17:00 on Thursday, Saturday and Sunday, and no lunch break on any of those days. Appointments can be arranged through KakaoTalk, LINE, WeChat, WhatsApp or phone, the same channels a visitor can use in advance to ask which toxin brand a given appointment plans to use.
UH CELL's genuine-product checklist, published on its news platform, applies at the point the vial is opened: a sealed box, an authentication sticker, a certification number, and the product opened in view of the patient before injection. That checklist applies to genuine product verification generally, and it works the same way whichever brand is labeled on the vial.
A patient who confirms the product name on the box and watches it opened before injection has checked the one variable this comparison settles only at the appointment itself: whether the syringe that day holds onabotulinumtoxinA, incobotulinumtoxinA, or another approved botulinum toxin.